Lissoni P, Brivio F, Fumagalli L, Galimberti C, Cataldo M, Marsili M T, Brivio O, Barni S, Tancini G, Angelini A
Division of Radiation Oncology, San Gerardo Hospital, Monza, Milano, Italy.
J Biol Regul Homeost Agents. 1994 Jan-Mar;8(1):32-5.
High levels of the macrophage activation marker neopterin have been described in metastatic cancer patients. Since macrophages may either counteract or stimulate tumor development, it is important to establish which macrophage activity is mainly related to neopterin release. The present study was carried out to evaluate neopterin levels in metastatic solid tumor patients in respect with the antitumor macrophage cytokine TNF and with soluble IL-2 receptor (SIL-2R), whose secretion is stimulated by macrophages and it is associated with the immunosuppressive status of cancer patients. The study included 35 patients with metastatic solid neoplasms. Serum levels of neopterin, TNF and SIL-2R were measured in blood samples collected during the morning. Abnormally high concentrations of neopterin were seen in 18/35 (51%) patients. Patients with high levels of neopterin showed significantly higher concentrations of SIL-2R than those with normal neopterin values, whereas no difference was found in TNF levels. This study would suggest that the increased secretion of neopterin may reflect macrophage-mediated immunosuppression in metastatic solid neoplasms, rather than to be associated with the antitumor activity of macrophages.
转移性癌症患者体内巨噬细胞激活标志物新蝶呤水平较高。由于巨噬细胞既可能对抗肿瘤发展，也可能刺激肿瘤发展，因此确定哪种巨噬细胞活性主要与新蝶呤释放相关很重要。本研究旨在评估转移性实体瘤患者的新蝶呤水平，并将其与抗肿瘤巨噬细胞细胞因子肿瘤坏死因子（TNF）以及可溶性白细胞介素-2受体（SIL-2R）进行对比，SIL-2R的分泌受巨噬细胞刺激，且与癌症患者的免疫抑制状态相关。该研究纳入了35例转移性实体瘤患者。于上午采集血样，检测其中新蝶呤、TNF和SIL-2R的血清水平。18/35（51%）的患者新蝶呤浓度异常升高。新蝶呤水平高的患者SIL-2R浓度显著高于新蝶呤值正常的患者，而TNF水平未发现差异。该研究表明，新蝶呤分泌增加可能反映转移性实体瘤中巨噬细胞介导的免疫抑制，而非与巨噬细胞的抗肿瘤活性相关。
